Drug intelligence / Profile preview

BI 765845

Development stage: Phase 1
Lead developer: Boehringer Ingelheim
Modality: Small Molecules
Administration: Intravenous

Overview

BI 765845 is an investigational intravenous drug being developed for the treatment of acute myocardial infarction (heart attack), specifically ST segment-elevation myocardial infarction (STEMI). It is designed to reduce infarct size, potentially limiting heart muscle damage following a heart attack. The drug is currently in Phase II clinical trials, where its safety, tolerability, and efficacy are being evaluated in patients who have recently experienced a heart attack. The developer and manufacturer is Boehringer Ingelheim.

Other names: C19orf10C-19orf10C 19orf10chromosome 19 open reading frame 10chromosome19 open reading frame 10chromosome-19 open reading frame 10MYDGFmyeloid-derived growth factorSF20SF-20SF 20stromal cell-derived growth factor SF20

Targets

IL34 (IL-34)LY6E (Lymphocyte antigen 6 complex locus E)

Beyond the preview

Go deeper on BI 765845.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BI 765845.